{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T10:32:28Z","timestamp":1716028348881},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiologie"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00117-023-01136-5","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T13:02:54Z","timestamp":1680008574000},"page":"366-370","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u201eBreast-like cancer of unknown primary\u201c","Breast-like cancer of unknown primary"],"prefix":"10.1007","volume":"63","author":[{"given":"Andreas","family":"Schneeweiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Buschhorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"1136_CR1","unstructured":"Empfehlungen der Kommission Mamma der Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie AGO. Diagnostik und Therapie fr\u00fcher und fortgeschrittener Mammakarzinome, Version 2022. www.ago-online.de\/leitlinien-empfehlungen\/leitlinien-empfehlungen\/kommission-mamma"},{"key":"1136_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-009-0554-3","volume":"119","author":"G Pentheroudakis","year":"2010","unstructured":"Pentheroudakis\u00a0G, Lazaridis\u00a0G, Pavlidis\u00a0N (2010) Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a\u00a0systematic review of published evidence. Breast Cancer Res Treat 119:1\u201311. https:\/\/doi.org\/10.1007\/s10549-009-0554-3","journal-title":"Breast Cancer Res Treat"},{"key":"1136_CR3","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/1097-0142(19920715)70:2<504::AID-CNCR2820700221>3.0.CO;2-T","volume":"70","author":"M Merson","year":"1992","unstructured":"Merson\u00a0M, Andreola\u00a0S, Galimberti\u00a0V et al (1992) Breast carcinoma presenting as axillary metastases without evidence of a\u00a0primary tumor. Cancer 70:504\u2013508","journal-title":"Cancer"},{"key":"1136_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00268-004-7290-y","volume":"28","author":"DK Blanchard","year":"2004","unstructured":"Blanchard\u00a0DK, Farley\u00a0DR (2004) Retrospective study of women presenting with axillary metastases from occult breast carcinoma. World J Surg 28:535\u2013539. https:\/\/doi.org\/10.1007\/s00268-004-7290-y","journal-title":"World J Surg"},{"key":"1136_CR5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00428-014-1545-2","volume":"464","author":"JD Hainsworth","year":"2014","unstructured":"Hainsworth\u00a0JD, Greco\u00a0FA (2014) Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care. Virchows Arch 464:393\u2013402. https:\/\/doi.org\/10.1007\/s00428-014-1545-2","journal-title":"Virchows Arch"},{"key":"1136_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-443-06652-8.50013-2","author":"DJ Dabbs","year":"2006","unstructured":"Dabbs\u00a0DJ (2006) Immunohistology of metastatic carcinoma of unknown primary. Diagn Immunohistochem. https:\/\/doi.org\/10.1016\/B978-0-443-06652-8.50013-2","journal-title":"Diagn Immunohistochem"},{"key":"1136_CR7","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","volume":"17","author":"S Moran","year":"2016","unstructured":"Moran\u00a0S, Mart\u00ednez-Card\u00fas\u00a0A, Sayols\u00a0S et al (2016) Epigenetic profiling to classify cancer of unknown primary: a\u00a0multicentre, retrospective analysis. Lancet Oncol 17:1386\u20131395. https:\/\/doi.org\/10.1016\/S1470-2045(16)30297-2","journal-title":"Lancet Oncol"},{"key":"1136_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/modpathol.3800731","volume":"20","author":"E Sasaki","year":"2007","unstructured":"Sasaki\u00a0E, Tsunoda\u00a0N, Hatanaka\u00a0Y et al (2007) Breast-specific expression of MGB1\/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod Pathol 20:208\u2013214","journal-title":"Mod Pathol"},{"key":"1136_CR9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2214\/ajr.159.3.1503012","volume":"159","author":"AJ Leibman","year":"1992","unstructured":"Leibman\u00a0AJ, Kossoff\u00a0MB (1992) Mammography in women with axillary lymphadenopathy and normal breasts on physical examination: value in detecting occult breast carcinoma. AJR Am J Roentgenol 159:493\u2013495. https:\/\/doi.org\/10.2214\/ajr.159.3.1503012","journal-title":"AJR Am J Roentgenol"},{"key":"1136_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1148\/radiology.207.1.9530316","volume":"207","author":"TM Kolb","year":"1998","unstructured":"Kolb\u00a0TM, Lichy\u00a0J, Newhouse\u00a0JH (1998) Occult cancer in women with dense breasts: detection with screening US\u2014diagnostic yield and tumor characteristics. Radiology 207:191\u2013199. https:\/\/doi.org\/10.1148\/radiology.207.1.9530316","journal-title":"Radiology"},{"key":"1136_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11060465","author":"M Costantini","year":"2021","unstructured":"Costantini\u00a0M, Montella\u00a0RA, Fadda\u00a0MP et al (2021) Axillary nodal metastases from carcinoma of unknown primary (CUPax): role of contrast-enhanced spectral mammography (CESM) in detecting occult breast cancer. J\u00a0Pers Med. https:\/\/doi.org\/10.3390\/jpm11060465","journal-title":"J Pers Med"},{"key":"1136_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3816\/cbc.2004.n.012","volume":"5","author":"C Chen","year":"2004","unstructured":"Chen\u00a0C, Orel\u00a0SG, Harris\u00a0E et al (2004) Outcome after treatment of patients with mammographically occult, magnetic resonance imaging-detected breast cancer presenting with axillary lymphadenopathy. Clin Breast Cancer 5:72\u201377. https:\/\/doi.org\/10.3816\/cbc.2004.n.012","journal-title":"Clin Breast Cancer"},{"key":"1136_CR13","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2214\/ajr.174.4.1741079","volume":"174","author":"IM Obdeijn","year":"2000","unstructured":"Obdeijn\u00a0IM, Brouwers-Kuyper\u00a0EM, Tilanus-Linthorst\u00a0MM et al (2000) MR imaging-guided sonography followed by fine-needle aspiration cytology in occult carcinoma of the breast. AJR Am J Roentgenol 174:1079\u20131084. https:\/\/doi.org\/10.2214\/ajr.174.4.1741079","journal-title":"AJR Am J Roentgenol"},{"key":"1136_CR14","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1245\/aso.2005.03.520","volume":"12","author":"CL Buchanan","year":"2005","unstructured":"Buchanan\u00a0CL, Morris\u00a0EA, Dorn\u00a0PL et\u00a0al (2005) Utility of breast magnetic resonance imaging in patients with occult primary breast cancer. Ann Surg Oncol 12:1045\u20131053. https:\/\/doi.org\/10.1245\/aso.2005.03.520","journal-title":"Ann Surg Oncol"},{"key":"1136_CR15","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s003300050694","volume":"9","author":"C Schorn","year":"1999","unstructured":"Schorn\u00a0C, Fischer\u00a0U, Luftner-Nagel\u00a0S et al (1999) MRI of the breast in patients with metastatic disease of unknown primary. Eur Radiol 9:470\u2013473. https:\/\/doi.org\/10.1007\/s003300050694","journal-title":"Eur Radiol"},{"key":"1136_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/s0002-9610(99)00221-4","volume":"178","author":"RS Henry-Tillman","year":"1999","unstructured":"Henry-Tillman\u00a0RS, Harms\u00a0SE, Westbrook\u00a0KC et al (1999) Role of breast magnetic resonance imaging in determining breast as a\u00a0source of unknown metastatic lymphadenopathy. Am J Surg 178:496\u2013500. https:\/\/doi.org\/10.1016\/s0002-9610(99)00221-4","journal-title":"Am J Surg"},{"key":"1136_CR17","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1148\/radiology.205.2.9356625","volume":"205","author":"EA Morris","year":"1997","unstructured":"Morris\u00a0EA, Schwartz\u00a0LH, Dershaw\u00a0DD et\u00a0al (1997) MR imaging of the breast in patients with occult primary breast carcinoma. Radiology 205:437\u2013440. https:\/\/doi.org\/10.1148\/radiology.205.2.9356625","journal-title":"Radiology"},{"key":"1136_CR18","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10434-000-0411-4","volume":"7","author":"JA Olson Jr","year":"2000","unstructured":"Olson\u00a0JA Jr, Morris\u00a0EA, Van Zee\u00a0KJ et\u00a0al (2000) Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol 7:411\u2013415. https:\/\/doi.org\/10.1007\/s10434-000-0411-4","journal-title":"Ann Surg Oncol"},{"key":"1136_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejso.2009.09.007","volume":"36","author":"J de Bresser","year":"2010","unstructured":"de Bresser\u00a0J, de Vos\u00a0B, van der Ent\u00a0F et\u00a0al (2010) Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a\u00a0systematic review. Eur J Surg Oncol 36:114\u2013119. https:\/\/doi.org\/10.1016\/j.ejso.2009.09.007","journal-title":"Eur J Surg Oncol"},{"key":"1136_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1245\/aso.2002.9.5.457","volume":"9","author":"I Bedrosian","year":"2002","unstructured":"Bedrosian\u00a0I (2002) Magnetic resonance imaging-guided biopsy of mammographically and clinically occult breast lesions. Ann Surg Oncol 9:457\u2013461. https:\/\/doi.org\/10.1245\/aso.2002.9.5.457","journal-title":"Ann Surg Oncol"},{"key":"1136_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.mric.2006.10.002","volume":"14","author":"D Floery","year":"2006","unstructured":"Floery\u00a0D, Helbich\u00a0TH (2006) MRI-Guided percutaneous biopsy of breast lesions: materials, techniques, success rates, and management in patients with suspected radiologic-pathologic mismatch. Magn Reson Imaging Clin N Am 14:411\u2013425. https:\/\/doi.org\/10.1016\/j.mric.2006.10.002","journal-title":"Magn Reson Imaging Clin N Am"},{"key":"1136_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1148\/radiology.220.1.r01jl0731","volume":"220","author":"CK Kuhl","year":"2001","unstructured":"Kuhl\u00a0CK, Morakkabati\u00a0N, Leutner\u00a0CC et al (2001) MR imaging\u2014guided large-core (14-gauge) needle biopsy of small lesions visible at breast MR imaging alone. Radiology 220:31\u201339. https:\/\/doi.org\/10.1148\/radiology.220.1.r01jl0731","journal-title":"Radiology"},{"key":"1136_CR23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cpet.2018.02.005","volume":"13","author":"HM Linden","year":"2018","unstructured":"Linden\u00a0HM, Peterson\u00a0LM, Fowler\u00a0AM (2018) Clinical potential of estrogen and progesterone receptor imaging. PET Clin 13:415\u2013422. https:\/\/doi.org\/10.1016\/j.cpet.2018.02.005","journal-title":"PET Clin"},{"key":"1136_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41523-019-0107-9","volume":"5","author":"EF Jones","year":"2019","unstructured":"Jones\u00a0EF, Ray\u00a0KM, Li\u00a0W et al (2019) Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol. NPJ Breast Cancer 5:12. https:\/\/doi.org\/10.1038\/s41523-019-0107-9","journal-title":"NPJ Breast Cancer"},{"key":"1136_CR25","unstructured":"National Cancer Institute (NCI) FES PET\/CT in predicting response in patients with newly diagnosed metastatic breast cancer receiving endocrine therapy (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02398773)"},{"key":"1136_CR26","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/0046-8177(90)90008-s","volume":"21","author":"PP Rosen","year":"1990","unstructured":"Rosen\u00a0PP, Kimmel\u00a0M (1990) Occult breast carcinoma presenting with axillary lymph node metastases: a follow-up study of 48\u00a0patients. Hum Pathol 21:518\u2013523. https:\/\/doi.org\/10.1016\/0046-8177(90)90008-s","journal-title":"Hum Pathol"},{"key":"1136_CR27","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.ejso.2012.08.022","volume":"38","author":"M He","year":"2012","unstructured":"He\u00a0M, Tang\u00a0L\u2011C, Yu\u00a0K\u2011D et al (2012) Treatment outcomes and unfavorable prognostic factors in patients with occult breast cancer. Eur J Surg Oncol 38:1022\u20131028. https:\/\/doi.org\/10.1016\/j.ejso.2012.08.022","journal-title":"Eur J Surg Oncol"},{"key":"1136_CR28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1524-4741.2009.00848.x","volume":"16","author":"X Wang","year":"2010","unstructured":"Wang\u00a0X, Zhao\u00a0Y, Cao\u00a0X (2010) Clinical benefits of mastectomy on treatment of occult breast carcinoma presenting axillary metastases. Breast\u00a0J 16:32\u201337. https:\/\/doi.org\/10.1111\/j.1524-4741.2009.00848.x","journal-title":"Breast J"},{"key":"1136_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.clon.2010.10.001","volume":"23","author":"SP Masinghe","year":"2011","unstructured":"Masinghe\u00a0SP, Faluyi\u00a0OO, Kerr\u00a0GR et\u00a0al (2011) Breast radiotherapy for occult breast cancer with axillary nodal metastases\u2014does it reduce the local recurrence rate and increase overall survival? Clin Oncol 23:95\u2013100. https:\/\/doi.org\/10.1016\/j.clon.2010.10.001","journal-title":"Clin Oncol"},{"key":"1136_CR30","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/1097-0142(19901001)66:7<1461::AID-CNCR2820660704>3.0.CO;2-Z","volume":"66","author":"N Ellerbroek","year":"1990","unstructured":"Ellerbroek\u00a0N, Holmes\u00a0F, Singletary\u00a0E et al (1990) Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer 66:1461\u20131467","journal-title":"Cancer"},{"key":"1136_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01420","author":"K-Y Huang","year":"2020","unstructured":"Huang\u00a0K\u2011Y, Zhang\u00a0J, Fu\u00a0W\u2011F et al (2020) Different clinicopathological characteristics and prognostic factors for occult and non-occult breast cancer: analysis of the SEER database. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2020.01420","journal-title":"Front Oncol"}],"container-title":["Die Radiologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-023-01136-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00117-023-01136-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-023-01136-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T16:03:47Z","timestamp":1682438627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00117-023-01136-5"}},"subtitle":["Implikationen f\u00fcr die radiologische Diagnostik","Implications for radiological diagnostics"],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1136"],"URL":"https:\/\/doi.org\/10.1007\/s00117-023-01136-5","relation":{},"ISSN":["2731-7048","2731-7056"],"issn-type":[{"value":"2731-7048","type":"print"},{"value":"2731-7056","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]},"assertion":[{"value":"8 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Schneeweiss hat Vortragshonorare erhalten von Celgene, Roche, Pfizer, AstraZeneca, Novartis, MSD, Tesaro, Lilly, Seagen, Gilead, GSK, Amgen, Pierre Fabre ohne Bezug zu diesem Artikel. L.\u00a0Buschhorn gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}